Telix Pharmaceuticals Ltd
TLXFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Telix Pharmaceuticals Ltd Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Source: Telix Pharmaceuticals Ltd — 20-F filed Feb 20, 2026
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 4 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated May 6, 2026.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-04-29 | Behrenbruch Christian · MD & Group CEO | Ordinary Shares | P — Open market or private purchase | +33,435 | 14.87 | SEC filing |
| 2026-04-28 | Behrenbruch Christian · MD & Group CEO | Ordinary Shares | P — Open market or private purchase | +34,500 | 14.48 | SEC filing |
Showing 2 of 2 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-03-29 | Smith Darren Charlton · Group Chief Financial Officer | Ordinary Shares | M — Exercise or conversion of derivative security | +1,111 | SEC filing |
| 2026-03-29 | Smith Darren Charlton · Group Chief Financial Officer | Share Rights | M — Exercise or conversion of derivative security | −1,111 | SEC filing |
Showing 2 of 2 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.